5-Hydroxytryptamine receptor 4 is a protein that in humans is encoded by the HTR4 gene.
This gene is a member of the family of human serotonin receptors, which are G protein-coupled receptors that stimulate cAMP production in response to serotonin (5-hydroxytryptamine). The gene product is a glycosylated transmembrane protein that functions in both the peripheral and central nervous system to modulate the release of various neurotransmitters. Multiple transcript variants encoding proteins with distinct C-terminal sequences have been described, but the full-length nature of some transcript variants has not been determined.
The receptor is located in the alimentary tract, urinary bladder, heart and adrenal gland as well as the central nervous system (CNS). In the CNS the receptor appears in the putamen, caudate nucleus, nucleus accumbens, globus pallidus, and substantia nigra, and to a lesser extent in the neocortex, raphe, pontine nuclei, and some areas of the thalamus. It has not been found in the cerebellum.
Internalization is isoform-specific.
Several drugs that act as 5-HT<sub>4</sub> selective agonists have recently been introduced into use in both scientific research and clinical medicine. Some drugs that act as 5-HT<sub>4</sub> agonists are also active as 5-HT<sub>3</sub> antagonists, such as metoclopramide, mosapride, renzapride, and zacopride, and so these compounds cannot be considered highly selective. Research in this area is ongoing. Amongst these agonists prucalopride has >150-fold higher affinity for 5-HT<sub>4</sub> receptors than for other receptors.
SB-207,145 radiolabeled with carbon-11 is used as a radioligand for 5-HT<sub>4</sub> in positron emission tomography studies in pigs and humans.